News

This clinical trial is a multi-center, randomized, double-blind, placebo-controlled Phase IIb study where 279 subjects have been enrolled. The trial is a standard flare design where patients with

Mr Greenberg brings to Disc Motion Technologies an extensive background in the orthopaedic and spine industries as well as executive leadership in various roles. Mr Greenberg’s prior experience

The study is being conducted in patients with stable angina undergoing percutaneous coronary intervention (PCI). The objectives of the Phase Ib study are to determine safety and tolerance

In his new role as vice president of discovery biology, Mr Wang will oversee the company’s growing portfolio of discovery biology service offerings. Prior to joining WuXi PharmaTech,

Under the auspices of this commercial license, Generex has established a branch office in exclusive Dubai Healthcare City operating as ‘Generex Biotechnology Corporation Mena’ (Middle East and North

These two drugs are the active constituents in Contrave, the company’s lead obesity product candidate, now in Phase III clinical trials. Naltrexone SR, a proprietary formulation developed by

Analysis of time to progression (TTP), the primary endpoint in the trial, failed to show a statistically significant improvement in the treatment arm, Specifid plus Leukine following Rituxan,

The technology acquired from LI-COR is said to broaden Pacific Biosciences’ existing intellectual property related to the SMRT (single molecule real time), sequencing method. Sequencing by incorporation generally

The disposable device removes amylase from whole saliva (and other body fluids) in a simple and efficient procedure. The device takes advantage of modified potato starch, which is